Davide Campari-Milano has announced a positive first-half performance, with sales driven by the popularity of aperitifs, tequila, and premium bourbon. The Italian distiller reported adjusted earnings before interest and taxes of €359.7 million, a significant increase from €310.9 million in the previous year.

During the first half, sales reached €1.46 billion, reflecting a strong 14% organic growth compared to the same period last year. This growth was primarily attributed to the impressive performance of aperitifs, tequila, and premium bourbon, as well as strategic price adjustments implemented during the period.

Net profit for the period rose to €216.9 million, an increase of 9% from €199.1 million in the previous year.

Looking ahead to the remainder of 2023, Chief Executive Bob Kunze-Concewitz expressed confidence in the positive business momentum across key brand-market combinations. Kunze-Concewitz expects volume growth to normalize and seasonality to play a role in driving performance. He also emphasized the company's strong brand equity and continued strength in the on-premise market.

Despite the impressive results, Campari expects the adjusted operating margin for the year to remain flat.

Amazon Commits to Changes in Marketplace Treatment

Nemetschek Reports Decrease in Q2 Net Profit

Leave A Reply

Your email address will not be published. Required fields are marked *

Related posts

Stocks Surge in Toronto as Earnings Season Approaches
News

Stocks Surge in Toronto as Earnings Season Approaches

Canadian stocks rise in anticipation of earnings season, with gains seen in technology and finance sectors. Manufacturin...

Etsy Shares Fall Despite Positive Revenue
News

Etsy Shares Fall Despite Positive Revenue

Etsy's stock falls despite beating revenue expectations, as management predicts decreased sales and intense retail compe...

FDA Allays Concerns Regarding Side Effects of Obesity Drugs
News

FDA Allays Concerns Regarding Side Effects of Obesity Drugs

The FDA dismisses concerns about the side effects of obesity drugs. GLP-1 receptor agonists have no association with sui...

Record Jump into U.S. Equities as Risks to Global Economy Heighten
News

Record Jump into U.S. Equities as Risks to Global Economy Heighten

Fund managers have made a significant shift from emerging markets to U.S. equities in response to growing risks in the g...